Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, finasteride-treated WAG/Rij rats showed a significant increase in spike-wave discharges when administered endogenous steroids THPROG and THDOC, indicating potential exacerbation of absence seizures.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

Finasteride blocks progesterone's effect on absence seizures in rats.

This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.

This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.

This study found that a novel saw palmetto supercritical CO2 extract effectively inhibits 5α-reductase type II in vitro, suggesting its potential for promoting prostate health in benign prostatic hyperplasia.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This review discusses finasteride's use in manipulating neuroactive steroid levels and its potential effects on behavior, reporting preclinical evidence and clinical observations but providing no new experimental results.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study found that dutasteride may offer neuroprotective effects on dopaminergic neurons in an animal model of early-stage Parkinson's disease, suggesting potential therapeutic use.

In this study, topical phenylephrine significantly reduced hair shedding and increased the force needed to pluck hair in women undergoing cosmetic procedures, suggesting its potential utility for traction alopecia.

This case report describes reversible hair loss in a patient taking aripiprazole, suggesting this side effect may be common among psychotropic medications.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

This study found that finasteride impaired stress reactivity and reduced exploratory and impulsive behaviors in rats, potentially by altering the hypothalamus-pituitary-adrenal axis function.

This study found that allopregnanolone has a bimodal effect on prolactin secretion in sheep, stimulating PRL mRNA expression but inhibiting hormone release under stress and pregnancy conditions.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.